{"id":"antiretroviral-medications","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Lipodystrophy"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Rash"}]},"_chembl":{"chemblId":"CHEMBL2108889","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Antiretrovirals work through multiple mechanisms depending on drug class: reverse transcriptase inhibitors block viral RNA-to-DNA conversion, protease inhibitors prevent viral protein maturation, integrase inhibitors block viral DNA integration into the host genome, and entry inhibitors prevent viral attachment or fusion with CD4+ cells. These drugs are typically used in combination (highly active antiretroviral therapy, HAART) to suppress viral load and restore immune function.","oneSentence":"Antiretroviral medications inhibit HIV replication by targeting viral enzymes or blocking viral entry into CD4+ T cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:02:01.605Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection"},{"name":"HIV-2 infection"}]},"trialDetails":[{"nctId":"NCT06819176","phase":"PHASE1","title":"Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People With HIV Receiving Antiretroviral Therapy","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-01-20","conditions":"Human Immunodeficiency Virus","enrollment":50},{"nctId":"NCT00326482","phase":"","title":"Liver Fibrosis in HIV-Infected Patients With Elevated Liver Enzymes on Antiretroviral Therapy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-07-31","conditions":"Liver Fibrosis, Steatohepatitis, Elevated Transaminases","enrollment":127},{"nctId":"NCT07266831","phase":"PHASE2, PHASE3","title":"A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-12-18","conditions":"Human Immunodeficiency Virus Type 1 (HIV-1) Infection","enrollment":570},{"nctId":"NCT05419024","phase":"PHASE2","title":"Imaging and Biopsy of People With HIV-1 Undergoing Analytic Treatment Interruption","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-01-09","conditions":"HIV","enrollment":50},{"nctId":"NCT05165810","phase":"NA","title":"Evaluation of Multiple Interventions to Improve HIV Treatment Outcomes Among People Who Inject Drugs in India","status":"ACTIVE_NOT_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2023-03-09","conditions":"HIV Infections","enrollment":800},{"nctId":"NCT00931463","phase":"PHASE4","title":"A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2009-09","conditions":"HIV Infections","enrollment":558},{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT05994742","phase":"PHASE3","title":"An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated SAM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Queen Mary University of London","startDate":"2024-07-15","conditions":"Severe Acute Malnutrition, HIV, Comorbidities and Coexisting Conditions","enrollment":674},{"nctId":"NCT04645693","phase":"","title":"The Impact of Oral Health in HIV Patients on Antiretroviral Therapy","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2021-02-24","conditions":"HIV, Periodontal Diseases, Caries","enrollment":227},{"nctId":"NCT06823596","phase":"NA","title":"The T Cell Activator of Cell Killing (\"TACK\") IT ON\" STUDY","status":"RECRUITING","sponsor":"University of Toronto","startDate":"2025-01-14","conditions":"Hiv","enrollment":26},{"nctId":"NCT07476339","phase":"PHASE4","title":"REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE: A Multi-Center, Single-Arm, Open-Label, Phase 4 Study Assessing the Safety and Efficacy of B/F/TAF in HIV-Positive Adults Returning to Care After Experiencing a Treatment Interruption of ≥12 Weeks","status":"NOT_YET_RECRUITING","sponsor":"CAN Community Health","startDate":"2026-03-23","conditions":"HIV -1 Infection, HIV (Human Immunodeficiency Virus), HIV","enrollment":200},{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT04860323","phase":"NA","title":"Analytical Treatment Interruption (ATI) to Assess the Immune System's Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 703/HPTN 081 AMP Study","status":"COMPLETED","sponsor":"HIV Vaccine Trials Network","startDate":"2021-05-28","conditions":"HIV Infection","enrollment":13},{"nctId":"NCT07202546","phase":"PHASE2","title":"A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)","status":"RECRUITING","sponsor":"ViiV Healthcare","startDate":"2026-02-11","conditions":"HIV Infections","enrollment":150},{"nctId":"NCT06468995","phase":"NA","title":"Antiviral Long Acting Drugs Landing in People Living With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"IRCCS San Raffaele","startDate":"2024-12-02","conditions":"HIV, Antiviral Agents","enrollment":120},{"nctId":"NCT07001319","phase":"PHASE1","title":"Study of GS-3242 in Participants With HIV-1; Substudy-05","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2025-05-29","conditions":"HIV-1-infection","enrollment":30},{"nctId":"NCT06680479","phase":"PHASE1","title":"Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy","status":"SUSPENDED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-04-01","conditions":"HIV-1","enrollment":30},{"nctId":"NCT07439562","phase":"NA","title":"Choice-Based Support for Adults Starting or Restarting Antiretroviral Therapy in Cape Town, South Africa","status":"NOT_YET_RECRUITING","sponsor":"University of Cape Town","startDate":"2026-02","conditions":"HIV Care Loss to Followup","enrollment":140},{"nctId":"NCT05398185","phase":"NA","title":"WiseApp for Spanish Speakers Living With HIV","status":"RECRUITING","sponsor":"Columbia University","startDate":"2023-03-01","conditions":"HIV Infections, Acquired Immune Deficiency Syndrome, Sexually Transmitted Diseases, Viral","enrollment":248},{"nctId":"NCT07433387","phase":"PHASE1, PHASE2","title":"Exploratory Study of LP-98 for Injection in ART-Naive HIV-Infected Individuals","status":"RECRUITING","sponsor":"Shanxi Kangbao Biological Product Co., Ltd.","startDate":"2026-01-29","conditions":"HIV","enrollment":30},{"nctId":"NCT02369406","phase":"PHASE2, PHASE3","title":"Early Infant HIV Treatment in Botswana","status":"ACTIVE_NOT_RECRUITING","sponsor":"Harvard School of Public Health (HSPH)","startDate":"2015-05-04","conditions":"HIV, Pediatric AIDS","enrollment":67},{"nctId":"NCT07209267","phase":"PHASE2","title":"Baricitinib Curative Repression of HIV-1","status":"NOT_YET_RECRUITING","sponsor":"Emory University","startDate":"2026-03","conditions":"HIV Infection, HIV","enrollment":20},{"nctId":"NCT04223778","phase":"PHASE3","title":"Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-18","conditions":"HIV Infection","enrollment":672},{"nctId":"NCT06488846","phase":"","title":"Innovative Administration of Long-Acting Injectables for HIV Treatment Enhancement at Home","status":"ENROLLING_BY_INVITATION","sponsor":"University of California, San Francisco","startDate":"2026-02-16","conditions":"HIV Infections","enrollment":1000},{"nctId":"NCT06886971","phase":"NA","title":"Strategies to AchieVe Viral Suppression for Youth With HIV","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2024-11-10","conditions":"Human Immunodeficiency Virus (HIV) Infection","enrollment":288},{"nctId":"NCT06411223","phase":"PHASE2","title":"Pharmacist-led Intervention for Injectable HIV Treatment for Women With Health-related Social Needs","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yale University","startDate":"2024-08-01","conditions":"Hiv","enrollment":50},{"nctId":"NCT05208697","phase":"NA","title":"Tele-Harm Reduction","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2022-10-10","conditions":"IV Drug Usage, HIV Infections, Hepatitis C","enrollment":100},{"nctId":"NCT07377760","phase":"NA","title":"Adaptive Text Messaging and Non-Monetary Incentives to Sustain ART Adherence Among Adolescents Living With HIV in Ethiopia","status":"NOT_YET_RECRUITING","sponsor":"Arba Minch University","startDate":"2026-03-09","conditions":"Antiretroviral Therapy (ART) Adherence Among Adolescents Living With HIV","enrollment":327},{"nctId":"NCT06375135","phase":"NA","title":"Efficacy of mHealth + e-Navigator Stepped Care Intervention for ART Adherence Among Latino Men With HIV","status":"RECRUITING","sponsor":"Florida International University","startDate":"2024-06-06","conditions":"ART Adherence","enrollment":250},{"nctId":"NCT06541028","phase":"NA","title":"Reducing Stigma in People Who Inject Drugs (PWID) With HIV Using a Rapid Start Antiretroviral Therapy Intervention (ART)","status":"RECRUITING","sponsor":"Yale University","startDate":"2025-11-04","conditions":"Hiv, Drug Use","enrollment":135},{"nctId":"NCT04233879","phase":"PHASE3","title":"Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-28","conditions":"HIV-1 Infection","enrollment":599},{"nctId":"NCT03497676","phase":"PHASE1, PHASE2","title":"More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-04-03","conditions":"HIV Infections","enrollment":168},{"nctId":"NCT06814041","phase":"NA","title":"Pilot RCT and Interview Study on an HIV Chatbot in Nigeria","status":"ACTIVE_NOT_RECRUITING","sponsor":"Christoph Pimmer","startDate":"2025-04-14","conditions":"HIV","enrollment":314},{"nctId":"NCT07357584","phase":"PHASE4","title":"Efficacy and Safety of Doravirine in the Rapid Initiation","status":"NOT_YET_RECRUITING","sponsor":"Fundación Huésped","startDate":"2026-07-13","conditions":"HIV-1-infection","enrollment":100},{"nctId":"NCT06647797","phase":"NA","title":"Enhancing Communication on Relationship Preservation, Safer Conception and PrEP to Promote HIV Testing in Uganda","status":"COMPLETED","sponsor":"Children's Mercy Hospital Kansas City","startDate":"2024-09-15","conditions":"HIV, Antenatal Care, Antiretroviral Therapy","enrollment":7666},{"nctId":"NCT06006546","phase":"PHASE1","title":"The Study of Immunization in People Living With HIV Undergoing an ATI for Elicitation of VRC01-lineage Antibodies","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-01-03","conditions":"Chronic HIV Infection","enrollment":35},{"nctId":"NCT07336797","phase":"PHASE2","title":"Effect of Empagliflozin on Metabolic Outcomes in Adults Living With HIV Receiving Dolutegravir-Based Therapy","status":"RECRUITING","sponsor":"Abdelrahman Mahmoud","startDate":"2025-09-01","conditions":"Metabolic Syndrome, Obesity & Overweight, HIV (Human Immunodeficiency Virus)","enrollment":66},{"nctId":"NCT01854775","phase":"PHASE2, PHASE3","title":"Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-05-06","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":129},{"nctId":"NCT05187429","phase":"PHASE1, PHASE2","title":"Low Dose Nivolumab in Adults Living With HIV on Antiretroviral Therapy","status":"RECRUITING","sponsor":"University of Melbourne","startDate":"2023-01-24","conditions":"HIV I Infection","enrollment":42},{"nctId":"NCT03696160","phase":"PHASE3","title":"The Late Presenter Treatment Optimisation Study","status":"COMPLETED","sponsor":"NEAT ID Foundation","startDate":"2019-03-05","conditions":"HIV/AIDS","enrollment":447},{"nctId":"NCT02969915","phase":"NA","title":"Strategies to Improve the HIV Care Continuum Among Key Populations in India","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2017-10-30","conditions":"HIV Infections","enrollment":2314},{"nctId":"NCT05122767","phase":"PHASE1, PHASE2","title":"Rifapentine and Isoniazid TB Preventive Therapy (3HP) for Children Taking Dolutegravir-based Antiretroviral Treatment (DOLPHIN KIDS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Aurum Institute NPC","startDate":"2023-05-24","conditions":"Tuberculosis, HIV","enrollment":92},{"nctId":"NCT07215325","phase":"PHASE4","title":"Got Doxy- 'Flipping the Script' on STI PEP","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-10-22","conditions":"Sexually Transmitted Infections (STI)","enrollment":200},{"nctId":"NCT06317051","phase":"PHASE3","title":"Optimising Metabolic Management for People With Human Immunodeficiency Virus (HIV) on Integrase Based Antiretroviral Therapy (ART)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kirby Institute","startDate":"2024-12-16","conditions":"HIV Infections, Weight Gain","enrollment":300},{"nctId":"NCT05642481","phase":"","title":"Therapeutic Drug Monitoring to oPtimize ANtiretroviral regimeNs in HIV-infected Women Who wAnt to Breastfeed","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2023-03-01","conditions":"HIV-1-infection","enrollment":16},{"nctId":"NCT03682848","phase":"PHASE3","title":"Safety and Efficacy of Dolutegravir/Lamivudine (DTG/3TC) in Therapy-naive Human Immunodeficiency Virus-1 (HIV-1) Infected Adolescents","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2019-05-06","conditions":"HIV Infections","enrollment":32},{"nctId":"NCT05979311","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2024-02-09","conditions":"HIV, HIV Infections","enrollment":473},{"nctId":"NCT06451341","phase":"","title":"IMplementation of CAB+RPV LA for People With HIV in Non-Metropolitan Areas","status":"RECRUITING","sponsor":"University of Nebraska","startDate":"2024-07-01","conditions":"HIV","enrollment":55},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":"HIV Infections","enrollment":1578},{"nctId":"NCT05310773","phase":"NA","title":"Couples Health CoOp Plus","status":"COMPLETED","sponsor":"RTI International","startDate":"2022-05-06","conditions":"HIV, Substance Use, Stigma, Social","enrollment":962},{"nctId":"NCT07030920","phase":"PHASE2","title":"Reducing Systemic Inflammation in People on Antiretroviral Therapy","status":"RECRUITING","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2025-09-30","conditions":"Human Immunodeficiency Virus (HIV), Cardiovascular Risk Factor","enrollment":150},{"nctId":"NCT07235852","phase":"NA","title":"Pilot Testing Into the Feasibility of the Developed Cognitive Behavioral Therapy Intervention","status":"RECRUITING","sponsor":"Khyber Medical University Peshawar","startDate":"2025-09-15","conditions":"HIV Infections, Depression, Anxiety Disorders","enrollment":50},{"nctId":"NCT04518228","phase":"","title":"Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-09-01","conditions":"HIV Infections, Tuberculosis","enrollment":205},{"nctId":"NCT06032546","phase":"PHASE2","title":"A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382","status":"TERMINATED","sponsor":"AbbVie","startDate":"2023-10-12","conditions":"Human Immuno-deficiency Virus (HIV) Disease","enrollment":163},{"nctId":"NCT07219862","phase":"NA","title":"Evaluating a Clinical Decision Support Tool for Antiretroviral Therapy Optimization","status":"NOT_YET_RECRUITING","sponsor":"Keck School of Medicine of USC","startDate":"2028-09-01","conditions":"HIV (Human Immunodeficiency Virus), Clinical Decision Support System (CDSS), Antiretroviral Therapy, Highly Active","enrollment":250},{"nctId":"NCT07115368","phase":"PHASE1","title":"Study of GS-1219 in Participants With HIV-1","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2025-08-11","conditions":"HIV-1-infection","enrollment":4},{"nctId":"NCT03981445","phase":"NA","title":"Integrated HIV Prevention and HCV Care for PWID","status":"ACTIVE_NOT_RECRUITING","sponsor":"Columbia University","startDate":"2019-11-14","conditions":"HIV Prevention, HCV, Opioid Use","enrollment":446},{"nctId":"NCT04479475","phase":"NA","title":"Social Networks and Methadone Maintenance Treatment Retention and Antiretroviral Therapy Retention in Tanzania","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2024-03-01","conditions":"Opioid-use Disorder, Adherence, Medication, HIV Infections","enrollment":58},{"nctId":"NCT06039579","phase":"PHASE2","title":"Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected Adults","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2023-10-25","conditions":"HIV Infections","enrollment":44},{"nctId":"NCT06497465","phase":"PHASE3","title":"Dolutegravir/Lamivudine Dual Therapy for ART-naïve People With HIV and TB Receiving Rifampin-based TB Treatment","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2025-09-18","conditions":"Tuberculosis, HIV","enrollment":150},{"nctId":"NCT01976715","phase":"","title":"Study of People With HIV Infection Who Have High Viral Loads Despite Combination Antiretroviral Therapy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-02-11","conditions":"Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus, AIDS Virus","enrollment":26},{"nctId":"NCT05780073","phase":"PHASE2","title":"Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antiretroviral Treatment","status":"COMPLETED","sponsor":"Fundació Institut Germans Trias i Pujol","startDate":"2023-10-16","conditions":"HIV Infection Primary","enrollment":60},{"nctId":"NCT06056037","phase":"NA","title":"Making ART Work Among Brazilian Youth","status":"RECRUITING","sponsor":"Brown University","startDate":"2023-10-01","conditions":"Hiv, Adherence, Medication","enrollment":72},{"nctId":"NCT03508310","phase":"NA","title":"A Waiting Room-Delivered Video to Enhance Clinical Outcomes Among Persons Living With HIV","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2016-06-01","conditions":"HIV Infections","enrollment":4003},{"nctId":"NCT07165639","phase":"","title":"The Eswatini Study on Neurocognitive Performance in Adolescents Living With HIV","status":"NOT_YET_RECRUITING","sponsor":"Eswatini Nazarene Health Institutions","startDate":"2025-11-30","conditions":"HIV (Human Immunodeficiency Virus)","enrollment":80},{"nctId":"NCT06814275","phase":"NA","title":"Project neuroARTEMIS","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2025-04-29","conditions":"Stimulant Use, Human Immunodeficiency Virus (HIV), Depression","enrollment":189},{"nctId":"NCT03385473","phase":"NA","title":"Individualized Antiretroviral Therapy","status":"COMPLETED","sponsor":"Hospital Italiano de Buenos Aires","startDate":"2017-10-05","conditions":"Pharmacogenetics, HIV, Drug Monitoring","enrollment":190},{"nctId":"NCT06762054","phase":"","title":"Investigating the Optimal Management of Dolutegravir Resistance","status":"RECRUITING","sponsor":"University of Nairobi","startDate":"2025-03-03","conditions":"HIV-1-infection","enrollment":6600},{"nctId":"NCT03635788","phase":"PHASE3","title":"The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-03-28","conditions":"HIV Infections","enrollment":456},{"nctId":"NCT02859558","phase":"PHASE2","title":"Early ART to Limit Infection and Establishment of Reservoir","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2017-01-24","conditions":"HIV-1 Infection","enrollment":195},{"nctId":"NCT05406583","phase":"PHASE1","title":"A Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-10-05","conditions":"HIV","enrollment":48},{"nctId":"NCT05604209","phase":"PHASE1","title":"Safety and Immunogenicity of HIV-1 Vaccines C62-M4 or C1C62-M3M4 in Persons With HIV-1 Suppressed on ART","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2022-10-13","conditions":"HIV Vaccine, HIV-1-infection","enrollment":18},{"nctId":"NCT07075146","phase":"PHASE3","title":"DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight or Obesity","status":"RECRUITING","sponsor":"José Antonio Mata Marín","startDate":"2025-05-05","conditions":"HIV - Human Immunodeficiency Virus, Obesity, Overweight and/or Obesity","enrollment":306},{"nctId":"NCT03754803","phase":"","title":"Description of Real World Antiviral Effectiveness and Sustainability of the 2-Drug Regimen Dolutegravir + Lamivudine in Untreated and Pre-treated Patients in Routine Clinical Care in Germany","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2018-11-08","conditions":"HIV Infections","enrollment":376},{"nctId":"NCT04530630","phase":"PHASE4","title":"Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF) After Renal Transplant","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2020-11-09","conditions":"HIV Infections, Renal Transplant Rejection","enrollment":20},{"nctId":"NCT06810973","phase":"NA","title":"Substance Use and HIV Action for Reentry and Engagement.","status":"ENROLLING_BY_INVITATION","sponsor":"Emory University","startDate":"2025-06-09","conditions":"HIV","enrollment":100},{"nctId":"NCT03800407","phase":"","title":"Contributing Factors for Poor HIV Treatment Response in Children With TB/HIV Coinfection","status":"COMPLETED","sponsor":"University of Florida","startDate":"2019-01-28","conditions":"Tuberculosis, Human Immunodeficiency Virus, Coinfection","enrollment":213},{"nctId":"NCT01741311","phase":"NA","title":"Secondary HIV Prevention and Adherence Among HIV-infected Drug Users","status":"COMPLETED","sponsor":"University of Connecticut","startDate":"2012-09","conditions":"Risk Behavior, Medication Adherence, HIV","enrollment":106},{"nctId":"NCT03978793","phase":"","title":"MyTPill: A Novel Strategy to Monitor Antiretroviral Adherence Among HIV+ Prescription Opioid Users","status":"COMPLETED","sponsor":"Ohio State University","startDate":"2021-02-01","conditions":"HIV-positive Individuals","enrollment":31},{"nctId":"NCT02470650","phase":"PHASE4","title":"Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive","status":"WITHDRAWN","sponsor":"Juan A. Arnaiz","startDate":"2015-06","conditions":"Patient Compliance, Antiretroviral Therapy Intolerance","enrollment":""},{"nctId":"NCT01778413","phase":"PHASE4","title":"Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine","status":"COMPLETED","sponsor":"Anna Cruceta","startDate":"2013-06-03","conditions":"HIV","enrollment":61},{"nctId":"NCT04087239","phase":"","title":"The University of Zimbabwe College of Health Science (UZ-CHS) BIRTH COHORT Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Zimbabwe","startDate":"2016-01-26","conditions":"HIV Infections, Immune Activation, Comorbidities","enrollment":1200},{"nctId":"NCT05729568","phase":"PHASE2","title":"A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2023-05-15","conditions":"HIV Infection","enrollment":83},{"nctId":"NCT05582694","phase":"PHASE2","title":"A Trial of Anti-CD4 Antibody UB-421 in Combination With Optimized Background Antiretroviral Therapy in Patients With Multi-Drug Resistant HIV-1 Infection","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-07-10","conditions":"Multi-Drug Resistant Hiv-1 Infection, HIV-1 Infection","enrollment":""},{"nctId":"NCT04571684","phase":"NA","title":"Evaluating HITSystem 2.1 to Improve Viral Suppression in Kenya","status":"COMPLETED","sponsor":"University of Kansas Medical Center","startDate":"2020-10-05","conditions":"HIV, Pregnancy","enrollment":1639},{"nctId":"NCT00187512","phase":"","title":"SCOPE: Observational Study of the Consequences of the Protease Inhibitor Era","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2000-03","conditions":"HIV Infections","enrollment":2500},{"nctId":"NCT04648046","phase":"PHASE1, PHASE2","title":"CAR-T Cells for HIV Infection","status":"RECRUITING","sponsor":"Steven Deeks","startDate":"2021-03-01","conditions":"HIV Infections","enrollment":18},{"nctId":"NCT06214052","phase":"PHASE2","title":"VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living With HIV-1","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2024-02-07","conditions":"HIV Infections","enrollment":22},{"nctId":"NCT01310023","phase":"","title":"Surveillance Monitoring for ART Toxicities Study in HIV Uninfected Children Born to HIV Infected Women","status":"COMPLETED","sponsor":"Harvard School of Public Health (HSPH)","startDate":"2007-03","conditions":"Antiretroviral Toxicity","enrollment":5169},{"nctId":"NCT07031063","phase":"PHASE4","title":"Safety, Tolerability and Effectiveness of DTG/3TC vs BIC/TAF/FTC in PWH Without Antiretroviral Experience","status":"RECRUITING","sponsor":"Instituto Mexicano del Seguro Social","startDate":"2025-04-01","conditions":"HIV Infection, Metabolic Syndrome, Antiretroviral Treatment","enrollment":124},{"nctId":"NCT06640192","phase":"PHASE2","title":"Administration of High Doses of Antiretroviral Drugs to Eliminate the Latent HIV-1 Reservoir","status":"RECRUITING","sponsor":"Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal","startDate":"2025-05-30","conditions":"HIV-1-infection","enrollment":24},{"nctId":"NCT03029689","phase":"PHASE3","title":"Clinical Trial to Evaluate the Effect of Raltegravir Intensification (1.200 mg QD) on the Gut Microbiota of Chronically HIV-1 Infected Subject Over Time: THE RAGTIME STUDY","status":"COMPLETED","sponsor":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","startDate":"2017-07-28","conditions":"HIV","enrollment":61},{"nctId":"NCT02656511","phase":"PHASE4","title":"Immediate Initiation of Antiretroviral Therapy During \"Hyperacute\" HIV Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2015-12","conditions":"HIV","enrollment":74},{"nctId":"NCT07004933","phase":"","title":"Rapid Antiretroviral Treatment Initiation With BIC/FTC/TAF in HIV-infected People Who Inject Drugs (PWID)","status":"COMPLETED","sponsor":"Hellenic Scientific Society for the Study of AIDS, Sexually Transmitted and Emerging Diseases","startDate":"2021-12-22","conditions":"HIV Positive People Who Inject Drugs","enrollment":37},{"nctId":"NCT00796263","phase":"PHASE3","title":"Antiretroviral Therapy for Acute and Chronic HIV Infection","status":"RECRUITING","sponsor":"SEARCH Research Foundation","startDate":"2009-05-13","conditions":"Acute HIV Infection, Chronic HIV Infection","enrollment":900},{"nctId":"NCT03952520","phase":"NA","title":"Scaling up an Evidence-based Intervention for Antiretroviral Therapy for PWID in Vietnam: an Implementation Trial","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2020-06-10","conditions":"HIV Infections, Drug Use","enrollment":1000},{"nctId":"NCT05585307","phase":"PHASE1","title":"Study of Novel Antiretrovirals in Participants With HIV-1","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2022-10-26","conditions":"HIV-1-infection","enrollment":49},{"nctId":"NCT05663580","phase":"","title":"Cohort Study of HIV-positive People, Treated With Long Acting Antiretroviral Therapy","status":"RECRUITING","sponsor":"Castagna Antonella","startDate":"2022-07-17","conditions":"HIV Infections","enrollment":1500},{"nctId":"NCT04098315","phase":"","title":"Italian Registry of HIV-1 Infected Patients With Drug-RESistant Virus to Reverse Transcriptase Inhibitors, InteGrasE and Viral Protease.","status":"RECRUITING","sponsor":"Castagna Antonella","startDate":"2017-12-14","conditions":"HIV-1-infection, Multi-Antiviral Resistance","enrollment":300},{"nctId":"NCT01808352","phase":"","title":"HPTN 073 Black Men Who Have Sex With Men (MSM) Pre-Exposure Prophylaxis (PrEP)","status":"COMPLETED","sponsor":"HIV Prevention Trials Network","startDate":"2013-08-15","conditions":"HIV","enrollment":226}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":986,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Antiretroviral medications","genericName":"Antiretroviral medications","companyName":"French National Agency for Research on AIDS and Viral Hepatitis","companyId":"french-national-agency-for-research-on-aids-and-viral-hepatitis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Antiretroviral medications inhibit HIV replication by targeting viral enzymes or blocking viral entry into CD4+ T cells. Used for HIV-1 infection, HIV-2 infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}